EW

In the past six months, Edwards Lifesciences' stock has been impacted by several events. The company reported strong second-quarter 2026 financial results, exceeding estimates with EPS of $0.78 and revenue of $1.74 billion, indicating robust demand for its therapies. FDA approval for the AUTUS Size-Adjustable Valve, a surgical pulmonary valve for pediatric patients, expanded its market and positively shifted the investment narrative. Analyst ratings have been positive, with Barclays initiating coverage with an "Overweight" rating and a $110 price target, and UBS reiterating a "Buy" rating with a $110 price target, leading to a consensus "Moderate Buy" rating and an average price target of $100.27 from 22 analysts. Conversely, there has been notable insider selling, such as Daniel J. Lippis selling 619 shares in October 2026. In January 2026, Edwards Lifesciences exited the JenaValve acquisition following an FTC ruling, refocusing capital on internal TAVR and mitral platforms. On October 8, 2026, the stock declined 3.49% without a specific catalyst, attributed to broader sector caution. Over the last three months (July 1, 2026, through September 28, 2026), the stock returned -7.74% compared to -3.19% for the Dow Jones Industrial Average.